[1]
Sheftel AD, Richardson DR, Prchal J, Ponka P. Mitochondrial iron metabolism and sideroblastic anemia. Acta haematologica. 2009:122(2-3):120-33. doi: 10.1159/000243796. Epub 2009 Nov 10
[PubMed PMID: 19907149]
[2]
Camaschella C. Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Seminars in hematology. 2009 Oct:46(4):371-7. doi: 10.1053/j.seminhematol.2009.07.001. Epub
[PubMed PMID: 19786205]
[3]
Severance S, Hamza I. Trafficking of heme and porphyrins in metazoa. Chemical reviews. 2009 Oct:109(10):4596-616. doi: 10.1021/cr9001116. Epub
[PubMed PMID: 19764719]
[4]
Sun F, Cheng Y, Chen C. Regulation of heme biosynthesis and transport in metazoa. Science China. Life sciences. 2015 Aug:58(8):757-64. doi: 10.1007/s11427-015-4885-5. Epub 2015 Jun 22
[PubMed PMID: 26100009]
[5]
Fitzsimons EJ, May A. The molecular basis of the sideroblastic anemias. Current opinion in hematology. 1996 Mar:3(2):167-72
[PubMed PMID: 9372069]
Level 3 (low-level) evidence
[6]
Massey AC. Microcytic anemia. Differential diagnosis and management of iron deficiency anemia. The Medical clinics of North America. 1992 May:76(3):549-66
[PubMed PMID: 1578956]
[7]
Brissot P, Bernard DG, Brissot E, Loréal O, Troadec MB. Rare anemias due to genetic iron metabolism defects. Mutation research. Reviews in mutation research. 2018 Jul-Sep:777():52-63. doi: 10.1016/j.mrrev.2018.06.003. Epub 2018 Jun 22
[PubMed PMID: 30115430]
[8]
Brattås MKL, Reikvam H. [Ring sideroblasts]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2017 Nov 14:137(21):. doi: 10.4045/tidsskr.17.0502. Epub 2017 Nov 13
[PubMed PMID: 29135187]
[9]
Li B, Wang JY, Liu JQ, Shi ZX, Peng SL, Huang HJ, Qin TJ, Xu ZF, Zhang Y, Fang LW, Zhang HL, Hu NB, Pan LJ, Qu SQ, Xiao ZJ. [Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2017 Dec 14:38(12):1012-1016. doi: 10.3760/cma.j.issn.0253-2727.2017.12.002. Epub
[PubMed PMID: 29365392]
Level 2 (mid-level) evidence
[10]
Harigae H. [Biology of sideroblastic anemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2017:58(4):347-352. doi: 10.11406/rinketsu.58.347. Epub
[PubMed PMID: 28484165]
[11]
Fujiwara T, Harigae H. Pathophysiology and genetic mutations in congenital sideroblastic anemia. Pediatrics international : official journal of the Japan Pediatric Society. 2013 Dec:55(6):675-9. doi: 10.1111/ped.12217. Epub
[PubMed PMID: 24003969]
[12]
Furuyama K, Kaneko K. Iron metabolism in erythroid cells and patients with congenital sideroblastic anemia. International journal of hematology. 2018 Jan:107(1):44-54. doi: 10.1007/s12185-017-2368-0. Epub 2017 Nov 14
[PubMed PMID: 29139060]
[13]
Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". American journal of hematology. 2019 Apr:94(4):475-488. doi: 10.1002/ajh.25397. Epub 2019 Jan 24
[PubMed PMID: 30618061]
[14]
Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. American journal of hematology. 2017 Mar:92(3):297-310. doi: 10.1002/ajh.24637. Epub
[PubMed PMID: 28188970]
[15]
Liapis K, Vrachiolias G, Spanoudakis E, Kotsianidis I. Vacuolation of early erythroblasts with ring sideroblasts: a clue to the diagnosis of linezolid toxicity. British journal of haematology. 2020 Sep:190(6):809. doi: 10.1111/bjh.16795. Epub 2020 Jun 8
[PubMed PMID: 32510577]
[16]
Ducamp S, Fleming MD. The molecular genetics of sideroblastic anemia. Blood. 2019 Jan 3:133(1):59-69. doi: 10.1182/blood-2018-08-815951. Epub 2018 Nov 6
[PubMed PMID: 30401706]
[17]
Harigae H, Furuyama K. Hereditary sideroblastic anemia: pathophysiology and gene mutations. International journal of hematology. 2010 Oct:92(3):425-31. doi: 10.1007/s12185-010-0688-4. Epub 2010 Sep 17
[PubMed PMID: 20848343]
[18]
Guernsey DL, Jiang H, Campagna DR, Evans SC, Ferguson M, Kellogg MD, Lachance M, Matsuoka M, Nightingale M, Rideout A, Saint-Amant L, Schmidt PJ, Orr A, Bottomley SS, Fleming MD, Ludman M, Dyack S, Fernandez CV, Samuels ME. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nature genetics. 2009 Jun:41(6):651-3. doi: 10.1038/ng.359. Epub 2009 May 3
[PubMed PMID: 19412178]
[19]
Smith OP, Hann IM, Woodward CE, Brockington M. Pearson's marrow/pancreas syndrome: haematological features associated with deletion and duplication of mitochondrial DNA. British journal of haematology. 1995 Jun:90(2):469-72
[PubMed PMID: 7794775]
[20]
Pearson HA, Lobel JS, Kocoshis SA, Naiman JL, Windmiller J, Lammi AT, Hoffman R, Marsh JC. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. The Journal of pediatrics. 1979 Dec:95(6):976-84
[PubMed PMID: 501502]
[21]
Torraco A, Bianchi M, Verrigni D, Gelmetti V, Riley L, Niceta M, Martinelli D, Montanari A, Guo Y, Rizza T, Diodato D, Di Nottia M, Lucarelli B, Sorrentino F, Piemonte F, Francisci S, Tartaglia M, Valente EM, Dionisi-Vici C, Christodoulou J, Bertini E, Carrozzo R. A novel mutation in NDUFB11 unveils a new clinical phenotype associated with lactic acidosis and sideroblastic anemia. Clinical genetics. 2017 Mar:91(3):441-447. doi: 10.1111/cge.12790. Epub 2016 May 25
[PubMed PMID: 27102574]
[22]
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19:127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11
[PubMed PMID: 27069254]
[23]
Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, Elena C, Gallì A, Walldin G, Della Porta MG, Raaschou-Jensen K, Travaglino E, Kallenbach K, Pietra D, Ljungström V, Conte S, Boveri E, Invernizzi R, Rosenquist R, Campbell PJ, Cazzola M, Hellström Lindberg E. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015 Jul 9:126(2):233-41. doi: 10.1182/blood-2015-03-633537. Epub 2015 May 8
[PubMed PMID: 25957392]
[24]
Broséus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, Rozman M, Lifermann F, Grossmann V, Haferlach T, Germing U, Luño E, Girodon F, Schnittger S, MPN and MPNr-EuroNet (COST Action BM0902). Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013 Sep:27(9):1826-31. doi: 10.1038/leu.2013.120. Epub 2013 Apr 18
[PubMed PMID: 23594705]
[25]
Rodriguez-Sevilla JJ, Calvo X, Arenillas L. Causes and Pathophysiology of Acquired Sideroblastic Anemia. Genes. 2022 Aug 30:13(9):. doi: 10.3390/genes13091562. Epub 2022 Aug 30
[PubMed PMID: 36140729]
[26]
Gill H, Choi WW, Kwong YL. Refractory anemia with ringed sideroblasts: more than meets the eye. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 10:28(32):e654-5. doi: 10.1200/JCO.2010.29.5220. Epub 2010 Aug 16
[PubMed PMID: 20713854]
[27]
Lefèvre C, Bondu S, Le Goff S, Kosmider O, Fontenay M. Dyserythropoiesis of myelodysplastic syndromes. Current opinion in hematology. 2017 May:24(3):191-197. doi: 10.1097/MOH.0000000000000325. Epub
[PubMed PMID: 28072603]
Level 3 (low-level) evidence
[28]
Pirruccello E, Luu HS, Chen W. Haematogone hyperplasia in copper deficiency. British journal of haematology. 2016 May:173(3):335. doi: 10.1111/bjh.13964. Epub 2016 Mar 7
[PubMed PMID: 26947425]
[30]
Van Dijck R, Goncalves Silva AM, Rijneveld AW. Luspatercept as Potential Treatment for Congenital Sideroblastic Anemia. The New England journal of medicine. 2023 Apr 13:388(15):1435-1436. doi: 10.1056/NEJMc2216213. Epub
[PubMed PMID: 37043658]
[31]
Shao Y, He L, Ding S, Fu R. Luspatercept for the treatment of congenital sideroblastic anemia: Two case reports. Current research in translational medicine. 2024 Mar:72(1):103438. doi: 10.1016/j.retram.2024.103438. Epub 2024 Jan 12
[PubMed PMID: 38244303]
Level 3 (low-level) evidence
[32]
Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, Marchetti M, Piga A, Tura S. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008 May:93(5):741-52. doi: 10.3324/haematol.12413. Epub 2008 Apr 15
[PubMed PMID: 18413891]
Level 1 (high-level) evidence
[33]
Cotter PD, May A, Li L, Al-Sabah AI, Fitzsimons EJ, Cazzola M, Bishop DF. Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Blood. 1999 Mar 1:93(5):1757-69
[PubMed PMID: 10029606]
[34]
Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. Journal of the National Comprehensive Cancer Network : JNCCN. 2022 Feb:20(2):106-117. doi: 10.6004/jnccn.2022.0009. Epub
[PubMed PMID: 35130502]
[35]
Lanino L, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Consagra A, Musto P, Cilloni D, Oliva EN, Palmieri R, Poloni A, Califano C, Capodanno I, Itri F, Elena C, Fozza C, Pane F, Pelizzari AM, Breccia M, Di Bassiano F, Crisà E, Ferrero D, Giai V, Barraco D, Vaccarino A, Griguolo D, Minetto P, Quintini M, Paolini S, Sanpaolo G, Sessa M, Bocchia M, Di Renzo N, Diral E, Leuzzi L, Genua A, Guarini A, Molteni A, Nicolino B, Occhini U, Rivoli G, Bono R, Calvisi A, Castelli A, Di Bona E, Di Veroli A, Ferrara F, Fianchi L, Galimberti S, Grimaldi D, Marchetti M, Norata M, Frigeni M, Sancetta R, Selleri C, Tanasi I, Tosi P, Turrini M, Giordano L, Finelli C, Pasini P, Naldi I, Santini V, Della Porta MG, Fondazione Italiana Sindromi Mielodisplastiche (FISiM) Clinical network (https://www.fisimematologia.it/). Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. American journal of hematology. 2023 Aug:98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24
[PubMed PMID: 37222267]
[36]
Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. The New England journal of medicine. 2020 Jan 9:382(2):140-151. doi: 10.1056/NEJMoa1908892. Epub
[PubMed PMID: 31914241]
[37]
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2024 Jan 20:403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1
[PubMed PMID: 38048786]
Level 1 (high-level) evidence
[38]
Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, Tsubaki K, Ishikawa J, Shibayama H, Matsumura I, Matsuda M. Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial. Cancer science. 2018 Oct:109(10):3209-3215. doi: 10.1111/cas.13739. Epub 2018 Aug 26
[PubMed PMID: 30007103]
[39]
Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Apr 10:27(11):1850-6. doi: 10.1200/JCO.2008.17.1058. Epub 2009 Mar 2
[PubMed PMID: 19255328]
[40]
Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, Gangat N, Tefferi A. Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. Leukemia. 2016 Nov:30(11):2273-2275. doi: 10.1038/leu.2016.216. Epub 2016 Aug 1
[PubMed PMID: 27479179]